Covid-19 Research

Review Article

OCLC Number/Unique Identifier:

Human Immunodeficiency Virus (HIV) Drug Resistance: A Global Narrative Review

Medicine Group    Start Submission

Maureen Nkandu Phiri and Steward Mudenda*

Volume2-Issue9
Dates: Received: 2021-09-15 | Accepted: 2021-09-29 | Published: 2021-09-30
Pages: 857-864

Abstract

Background: Antiretroviral Therapy (ART) has significantly improved Human Immunodeficiency Virus (HIV) patients’ survival rates. However, the emergence of HIV Drug Resistance (HIVDR) has markedly reduced the effectiveness of Antiretroviral Therapy (ART).

Aim: This narrative review was conducted to review published studies on HIV drug resistance and its consequences.

Materials and methods: A literature search for this narrative review was carried out and the following databases were used PubMed, Google Scholar, and The Lancet. The cited articles were published from 1999 to 2021. The keywords used in the search of literature included ‘Antiretroviral therapy’, ‘resistance’, and ‘Human Immunodeficiency Virus drug resistance’, ‘HIV’, ‘HIV drug resistance’, ‘HIV vaccines’, and the Boolean word ‘AND’.

Results: There is a high prevalence of HIV drug resistance globally that has been associated with some factors such as older age, non-adherence to treatment, long treatment duration, lower cell count and high viral load. HIV drug resistance may lead to treatment failure, prolongation of the time required to achieve viral suppression and leads to increased mortality. Increasing access to viral load monitoring can help mitigate HIV drug resistance.

Conclusion: HIV drug resistance is a global threat to public health and has been associated with increased morbidity and mortality. Therefore, there is a need for more research to be carried out and various strategies like the use of antiretrovirals with a high genetic barrier to resistance need to be put in place to prevent further spread resistance. HIVDR must be monitored frequently taking into consideration the geographic variability. There is an urgent need for the development of anti-HIV vaccines that will help to prevent further transmission and spread of HIV.

FullText HTML FullText PDF DOI: 10.37871/jbres1323


Certificate of Publication




Copyright

© 2021 Phiri MN, et al. Distributed under Creative Commons CC-BY 4.0

How to cite this article

Phiri MN, Mudenda S. Human Immunodeficiency Virus (HIV) Drug Resistance: A Global Narrative Review. J Biomed Res Environ Sci. 2021 Sept 30; 2(9): 857-864. doi: 10.37871/jbres1323, Article ID: JBRES1323, Available at: https://www.jelsciences.com/articles/jbres1323.pdf


Subject area(s)

University/Institute

References


  1. Iwuji C, Newell ML. Towards control of the global HIV epidemic: Addressing the middle-90 challenge in the UNAIDS 90-90-90 target. PLoS Med. 2017 May 2;14(5):e1002293. doi: 10.1371/journal.pmed.1002293. PMID: 28464003; PMCID: PMC5412986.
  2. Piot P, Quinn TC. Response to the AIDS pandemic--a global health model. N Engl J Med. 2013 Jun 6;368(23):2210-8. doi: 10.1056/NEJMra1201533. Erratum in: N Engl J Med. 2013 Sep 19;369(12):1180. PMID: 23738546; PMCID: PMC3777557.
  3. Nakazwe C, Michelo C, Sandøy IF, Fylkesnes K. Contrasting HIV prevalence trends among young women and men in Zambia in the past 12 years: data from demographic and health surveys 2002-2014. BMC Infect Dis. 2019 May 17;19(1):432. doi: 10.1186/s12879-019-4059-3. PMID: 31101081; PMCID: PMC6525340.
  4. Aghokeng AF, Kouanfack C, Eymard-Duvernay S, Butel C, Edoul GE, Laurent C, Koulla-Shiro S, Delaporte E, Mpoudi-Ngole E, Peeters M. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months’ antiretroviral therapy experience in Cameroon. J Int AIDS Soc. 2013 Jan 31;16(1):18004. doi: 10.7448/IAS.16.1.18004. PMID: 23374858; PMCID: PMC3562358.
  5. Panos G, Samonis G, Alexiou VG, Kavarnou GA, Charatsis G, Falagas ME. Mortality and morbidity of HIV infected patients receiving HAART: a cohort study. Curr HIV Res. 2008 May;6(3):257-60. doi: 10.2174/157016208784324976. PMID: 18473789.
  6. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med. 2005 Mar;6(2):99-106. doi: 10.1111/j.1468-1293.2005.00271.x. PMID: 15807715.
  7. Sharma B. Drug Resistance in HIV-1: Genetic and Molecular Bases, Mechanisms, and Strategies to Combat the Issue. Biochem Anal Biochem. 2014;04(01):1–2. doi: 10.4172/2161-1009.1000e153
  8. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. Diversity considerations in HIV-1 vaccine selection. Science. 2002 Jun 28;296(5577):2354-60. doi: 10.1126/science.1070441. PMID: 12089434.
  9. WHO. HIV Drug Resistance Report 2019. Geneva, Switzerland. 2019. https://bit.ly/3m39dro
  10. Jordan MR, Winsett J, Tiro A, Bau V, Berbara RS, Rowley C, Bellosillo N, Wanke C, Coakley EP. HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels. World J AIDS. 2013 Jun;3(2):71-78. doi: 10.4236/wja.2013.32010. PMID: 25664219; PMCID: PMC4319662.
  11. Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice. J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927. PMID: 20981785.
  12. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M. HIV-1 drug resistance in newly infected individuals. JAMA. 1999 Sep 22-29;282(12):1135-41. doi: 10.1001/jama.282.12.1135. PMID: 10501116.
  13. UNAIDS JUNP on H. 90‐90‐90 an ambitious treatment target to help end the AIDS epidemic. UNAIDS Geneva, Switzerland; 2014. https://bit.ly/3oiyBvW
  14. WHO. Meeting report on assessment of World Health Organization HIV drug resistance early warning indicators: report of the Early Advisory Indicator Panel meeting. 2012. https://bit.ly/2Y2hbcw
  15. Dünya Sağlık Örgütü (DSÖ/WHO). Global Report on Early Warning Indicators of HIV Drug Resistance. World Heal Organization. 2016;64. https://bit.ly/3ijGD46
  16. Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Wit FW, van Vugt M, Stevens WS, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER) Investigators. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012 Apr;12(4):307-17. doi: 10.1016/S1473-3099(11)70255-9. Epub 2011 Oct 27. PMID: 22036233.
  17. Xing H, Ruan Y, Li J, Shang H, Zhong P, Wang X, Liao L, Li H, Zhang M, Xue Y, Wang Z, Su B, Liu W, Dong Y, Ma Y, Li H, Qin G, Chen L, Pan X, Chen X, Peng G, Fu J, Chen RY, Kang L, Shao Y; Chinese National HIVDR Surveillance and Monitoring Network. HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients. PLoS One. 2013;8(2):e54917. doi: 10.1371/journal.pone.0054917. Epub 2013 Feb 6. PMID: 23405098; PMCID: PMC3566114.
  18. Azam M, Malik A, Rizvi M, Rai A. Trends of drug-resistance-associated mutations in the reverse transcriptase gene of HIV type 1 isolates from North India. Arch Virol. 2014 Apr;159(4):719-25. doi: 10.1007/s00705-013-1889-y. Epub 2013 Oct 19. PMID: 24142273.
  19. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med. 2011 Aug 18;365(7):637-46. doi: 10.1056/NEJMra1004180. PMID: 21848464.
  20. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER). Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):23-31. doi: 10.1097/QAI.0b013e318227fc34. PMID: 21694603.
  21. Yashik S, Maurice M. Predicting a single HIV drug resistance measure from three international interpretation gold standards. Asian Pac J Trop Med. 2012 Jul;5(7):566-72. doi: 10.1016/S1995-7645(12)60100-X. PMID: 22647821.
  22. WHO. HIV drug resistance report 2012. 2012. https://bit.ly/3kRGS85
  23. Günthard HF, Calvez V, Paredes R, Pillay D, Shafer RW, Wensing AM, Jacobsen DM, Richman DD. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel. Clin Infect Dis. 2019 Jan 7;68(2):177-187. doi: 10.1093/cid/ciy463. PMID: 30052811; PMCID: PMC6321850.
  24. Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O’Connor E, Rochford A, Low J, Coakely P, O’Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29. PMID: 26620652; PMCID: PMC4741360.
  25. Kityo C, Boerma RS, Sigaloff KCE, Kaudha E, Calis JCJ, Musiime V, Balinda S, Nakanjako R, Boender TS, Mugyenyi PN, Rinke de Wit TF. Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children. J Antimicrob Chemother. 2017 Sep 1;72(9):2587-2595. doi: 10.1093/jac/dkx188. PMID: 28673027; PMCID: PMC5890670.
  26. Ahmed Y, Tian M, Gao Y. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies. AIDS Res Ther. 2017 Sep 12;14(1):50. doi: 10.1186/s12981-017-0178-3. PMID: 28893278; PMCID: PMC5594608.
  27. Cho MW, Kim YB, Lee MK, Gupta KC, Ross W, Plishka R, Buckler-White A, Igarashi T, Theodore T, Byrum R, Kemp C, Montefiori DC, Martin MA. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J Virol. 2001 Mar;75(5):2224-34. doi: 10.1128/JVI.75.5.2224-2234.2001. PMID: 11160726; PMCID: PMC114806.
  28. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology. 2006 Jun 20;350(1):34-47. doi: 10.1016/j.virol.2006.02.032. Epub 2006 Apr 17. PMID: 16616287.
  29. Haynes BF, Moody MA, Alam M, Bonsignori M, Verkoczy L, Ferrari G, Gao F, Tomaras GD, Liao HX, Kelsoe G. Progress in HIV-1 vaccine development. J Allergy Clin Immunol. 2014 Jul;134(1):3-10; quiz 11. doi: 10.1016/j.jaci.2014.04.025. Epub 2014 Jun 26. PMID: 25117798; PMCID: PMC4133697.
  30. Tang MW, Liu TF, Shafer RW. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012;55(2):98-101. doi: 10.1159/000331998. Epub 2012 Jan 24. PMID: 22286876; PMCID: PMC7068798.
  31. Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2012 Oct;56(10):5000-8. doi: 10.1128/AAC.00591-12. Epub 2012 Jun 25. PMID: 22733071; PMCID: PMC3457356.
  32. Haggblom A. Antiretroviral drug resistance and treatment outcomes of Human Immunodeficiency Virus type-1, implications for low and middle-income countries. Karolinska Institutet; 2016. https://bit.ly/2Zx4hDu
  33. Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012 Jun 18;72(9):e1-25. doi: 10.2165/11633630-000000000-00000. PMID: 22686620; PMCID: PMC3689909.
  34. Boucher CA, Bobkova MR, Geretti AM, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Dorr P, Vandamme AM. State of the Art in HIV Drug Resistance: Science and Technology Knowledge Gap. AIDS Rev. 2018 Jan-Mar;20(1):27-42. PMID: 29628515.
  35. Margeridon-Thermet S, Shafer RW. Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses. 2010 Dec 1;2(12):2696-739. doi: 10.3390/v2122696. PMID: 21243082; PMCID: PMC3020796.
  36. Fokam J, Takou D, Semengue ENJ, Teto G, Beloumou G, Dambaya B, Santoro MM, Mossiang L, Billong SC, Cham F, Sosso SM, Temgoua ES, Nanfack AJ, Moudourou S, Kamgaing N, Kamgaing R, Ngako Pamen JN, Etame MMN, Bissek AZ, Elat JN, Moussi EE, Colizzi V, Perno CF, Ndjolo A; VIROFORUM. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. Antimicrob Resist Infect Control. 2020 Aug 26;9(1):143. doi: 10.1186/s13756-020-00799-2. PMID: 32843050; PMCID: PMC7449072.
  37. Rossouw TM, Feucht UD, Melikian G, van Dyk G, Thomas W, du Plessis NM, Avenant T. Factors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South Africa. PLoS One. 2015 Jul 21;10(7):e0133452. doi: 10.1371/journal.pone.0133452. PMID: 26196688; PMCID: PMC4510388.
  38. Xing H, Wang X, Liao L, Ma Y, Su B, Fu J, He J, Chen L, Pan X, Dong Y, Liu W, Hsi JH, Yang L, Ruan Y, Shao Y. Incidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatment. PLoS One. 2013 Apr 30;8(4):e62408. doi: 10.1371/journal.pone.0062408. PMID: 23638072; PMCID: PMC3640055.
  39. Zhou Y, Lu J, Wang J, Yan H, Li J, Xu X, Zhang Z, Qiu T, Ding P, Fu G, Huan X, Hu H. Prevalence of HIV Antiretroviral Drug Resistance and Its Impacts on HIV-1 Virological Failures in Jiangsu, China: A Cross-Sectional Study. Biomed Res Int. 2016;2016:1752437. doi: 10.1155/2016/1752437. Epub 2016 Oct 11. PMID: 27807537; PMCID: PMC5078637.
  40. Ekong E, Ndembi N, Okonkwo P, Dakum P, Idoko J, Banigbe B, Okuma J, Agaba P, Blattner W, Adebamowo C, Charurat M. Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria. AIDS Res Ther. 2020 Feb 17;17(1):7. doi: 10.1186/s12981-020-0261-z. PMID: 32066473; PMCID: PMC7027291.
  41. Jose S, Quinn K, Dunn D, Cox A, Sabin C, Fidler S; UK CHIC and UK HDRD Steering Committees. Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. HIV Med. 2016 May;17(5):368-72. doi: 10.1111/hiv.12302. Epub 2015 Aug 25. PMID: 26306942; PMCID: PMC4949527.
  42. Crowell TA, Pinyakorn S, Sacdalan C, Kroon E, Colby DJ, Puttamaswin S, Ubolyam S, Trichavaroj R, Butterworth O, Turk E, Mccullough C, Chomont N, de Souza M, Robb ML, Phanuphak N, Ananworanich J; RV254/SEARCH010 Study Group. Viral Blips After Treatment Initiation During Acute Human Immunodeficiency Virus Infection. Clin Infect Dis. 2020 Jun 10;70(12):2706-2709. doi: 10.1093/cid/ciz936. PMID: 31550044; PMCID: PMC7286371.
  43. Boateng D, Awunyo-Vitor D. Knowledge, Perceptions, and Practices on Antiretroviral Therapy in Farming Communities in Ghana: A Study of HIV Positive Women. Public Heal Res. 2012;2(5):136-142.
  44. Ibrahim Y, Sutan R, Bin K, Latif A, Amara A, Adam I. Poor Adherence to Antiretroviral Therapy and associated factors among people living with HIV in Omdurman city, Sudan. Malaysian J Public Heal Med. 2014;14(1):90–101. https://bit.ly/3CZ1fpV
  45. Kinyua JG, Lihana RW, Kiptoo M, Muasya T, Odera I, Muiruri P, Songok EM. Antiretroviral resistance among HIV-1 patients on first-line therapy attending a comprehensive care clinic in Kenyatta National Hospital, Kenya: a retrospective analysis. Pan Afr Med J. 2018 Apr 2;29:186. doi: 10.11604/pamj.2018.29.186.10796. PMID: 30061964; PMCID: PMC6061825.
  46. Denison JA, Koole O, Tsui S, Menten J, Torpey K, van Praag E, Mukadi YD, Colebunders R, Auld AF, Agolory S, Kaplan JE, Mulenga M, Kwesigabo GP, Wabwire-Mangen F, Bangsberg DR. Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia. AIDS. 2015 Jan 28;29(3):361-71. doi: 10.1097/QAD.0000000000000543. PMID: 25686684; PMCID: PMC4728173.
  47. Qiao S, Zhang Y, Li X, Menon JA. Facilitators and barriers for HIV-testing in Zambia: A systematic review of multi-level factors. PLoS ONE. 2018;13:e0192327. https://bit.ly/3zTi5Vg
  48. Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis. 2013 Jun 15;207 Suppl 2(Suppl 2):S49-56. doi: 10.1093/infdis/jit107. PMID: 23687289; PMCID: PMC3708738.
  49. Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Avihingsanon A, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC; A5288 Team. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019 Sep;6(9):e588-e600. doi: 10.1016/S2352-3018(19)30146-8. Epub 2019 Jul 29. PMID: 31371262; PMCID: PMC6857629.
  50. Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, Rinke de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D’Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. Erratum in: PLoS Med. 2015 Jun;12(6):e1001845. PMID: 25849352; PMCID: PMC4388826.
  51. Ferreira ACG, Coelho LE, Grinsztejn E, Jesus CS, Guimarães ML, Veloso VG, Grinsztejn B, Cardoso SW. Transmitted drug resistance in patients with acute/recent HIV infection in Brazil. Braz J Infect Dis. 2017 Jul-Aug;21(4):396-401. doi: 10.1016/j.bjid.2017.03.013. Epub 2017 May 21. PMID: 28539254.
  52. Pang X, Tang K, He Q, Huang J, Fang N, Zhou X, Zhu Q, Wu X, Shen Z, Liang S. HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China. BMC Infect Dis. 2021 Feb 8;21(1):160. doi: 10.1186/s12879-021-05854-w. PMID: 33557775; PMCID: PMC7871613.
  53. Zuo L, Liu K, Liu H, Hu Y, Zhang Z, Qin J, Xu Q, Peng K, Jin X, Wang JH, Zhang C. Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017). EClinicalMedicine. 2020 Jan 5;18:100238. doi: 10.1016/j.eclinm.2019.100238. Erratum in: EClinicalMedicine. 2021 Mar 12;33:100696. PMID: 31922125; PMCID: PMC6948268.
  54. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, Sawyer AW, Hamers RL, Ndembi N, Pillay D, Bertagnolio S. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012 Oct 6;380(9849):1250-8. doi: 10.1016/S0140-6736(12)61038-1. Epub 2012 Jul 23. Erratum in: Lancet. 2012 Oct 6;380(9849):1230. PMID: 22828485; PMCID: PMC3790969.
  55. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, Kaleebu P, Watera C, Aghokeng A, Mutenda N, Dzangare J, Hone S, Hang ZZ, Garcia J, Garcia Z, Marchorro P, Beteta E, Giron A, Hamers R, Inzaule S, Frenkel LM, Chung MH, de Oliveira T, Pillay D, Naidoo K, Kharsany A, Kugathasan R, Cutino T, Hunt G, Avila Rios S, Doherty M, Jordan MR, Bertagnolio S. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018 Mar;18(3):346-355. doi: 10.1016/S1473-3099(17)30702-8. Epub 2017 Dec 5. Erratum in: Lancet Infect Dis. 2017 Dec 15;: PMID: 29198909; PMCID: PMC5835664.
  56. Ngo-Giang-Huong N, Huynh THK, Dagnra AY, Toni TD, Maiga AI, Kania D, Eymard-Duvernay S, Peeters M, Soulie C, Peytavin G, Rekacewicz C, Chaix ML, Aghokeng AF; ANRS 12333 Study Group. Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries. J Antimicrob Chemother. 2019 Feb 1;74(2):462-467. doi: 10.1093/jac/dky443. PMID: 30418575; PMCID: PMC6337899.
  57. Bissio E, Barbás MG, Bouzas MB, Cudolá A, Salomón H, Espínola L, Fernández Giuliano S, Kademián S, Mammana L, Ornani ML, Ravasi G, Vila M, Zapiola I, Falistocco C. Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15. J Antimicrob Chemother. 2017 Feb;72(2):504-510. doi: 10.1093/jac/dkw445. Epub 2016 Oct 26. PMID: 27789684.
  58. Zhang Y, Fogel JM, Guo X, Clarke W, Breaud A, Cummings V, Hamilton EL, Ogendo A, Kayange N, Panchia R, Dominguez K, Chen YQ, Sandfort T, Eshleman SH. Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa. AIDS. 2018 Jun 19;32(10):1301-1306. doi: 10.1097/QAD.0000000000001839. PMID: 29794492; PMCID: PMC6146920.
  59. Kouamou V, Varyani B, Shamu T, Mapangisana T, Chimbetete C, Mudzviti T, Manasa J, Katzenstein D. Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment. AIDS Res Hum Retroviruses. 2020 Jul;36(7):566-573. doi: 10.1089/AID.2019.0232. Epub 2020 Apr 2. PMID: 32138527.
  60. Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, Doherty M, Revill P, Bertagnolio S. Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa. J Infect Dis. 2017 May 1;215(9):1362-1365. doi: 10.1093/infdis/jix089. Erratum in: J Infect Dis. 2017 Nov 15;216(8):1048. PMID: 28329236; PMCID: PMC5451603.
  61. Cambiano V, Bertagnolio S, Jordan MR, Lundgren JD, Phillips A. Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings. J Infect Dis. 2013 Jun 15;207 Suppl 2:S57-62. doi: 10.1093/infdis/jit111. PMID: 23687290.
  62. Luo XL, Mo LD, Su GS, Huang JP, Wu JY, Su HZ, Huang WH, Luo SD, Ni ZY. Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy. J Pharmacol Sci. 2019 Apr;139(4):275-279. doi: 10.1016/j.jphs.2018.11.016. Epub 2019 Jan 17. PMID: 30928089.
  63. Boender TS, Hoenderboom BM, Sigaloff KC, Hamers RL, Wellington M, Shamu T, Siwale M, Labib Maksimos EE, Nankya I, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Ondoa P, Rinke de Wit TF. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. Clin Infect Dis. 2015 Dec 1;61(11):1749-58. doi: 10.1093/cid/civ656. Epub 2015 Aug 3. PMID: 26240203.
  64. Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R, Bangsberg DR, Yiannoutsos CT, Deeks SG, Martin JN. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. AIDS. 2014 Sep 10;28(14):2097-107. doi: 10.1097/QAD.0000000000000349. PMID: 24977440; PMCID: PMC4317283.
  65. De Beaudrap P, Thiam M, Diouf A, Toure-Kane C, Ngom-Guèye NF, Vidal N, Mboup S, Ndoye I, Sow PS, Delaporte E; ANRS 1215 Study Group. Risk of virological failure and drug resistance during first and second-line antiretroviral therapy in a 10-year cohort in Senegal: results from the ANRS 1215 cohort. J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):381-7. doi: 10.1097/QAI.0b013e31827a2a7a. PMID: 23117504.
  66. Hamers RL, Sigaloff KC, Kityo C, Mugyenyi P, de Wit TF. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS. 2013 Jan;8(1):19-26. doi: 10.1097/COH.0b013e32835b7f94. PMID: 23143140.
  67. WHO. Guidelines on the public health response to pretreatment HIV drug resistance. 2017. https://bit.ly/3D0lEez
  68. WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. 2018. https://bit.ly/3m5HaaV
  69. Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, Popoff E, Bansback N, Nsanzimana S, Thorlund K, Mills EJ. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2016 Nov;3(11):e510-e520. doi: 10.1016/S2352-3018(16)30091-1. Epub 2016 Sep 6. PMID: 27658869.
  70. Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, Manzini T, Mathe M, Moosa Y, Nash J, Nel J, Pakade Y, Woods J, Van Zyl G, Conradie F, Venter F. Adult antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017 Jul 15;18(1):776. doi: 10.4102/sajhivmed.v18i1.776. PMID: 29568644; PMCID: PMC5843236.
  71. Amstutz A, Nsakala BL, Vanobberghen F, Muhairwe J, Glass TR, Namane T, Mpholo T, Battegay M, Klimkait T, Labhardt ND. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho. PLoS Med. 2020 Sep 16;17(9):e1003325. doi: 10.1371/journal.pmed.1003325. PMID: 32936795; PMCID: PMC7494118.
  72. Boyer S, March L, Kouanfack C, Laborde-Balen G, Marino P, Aghokeng AF, Mpoudi-Ngole E, Koulla-Shiro S, Delaporte E, Carrieri MP, Spire B, Laurent C, Moatti JP; Stratall ANRS 12110/ESTHER Study Group. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect Dis. 2013 Jul;13(7):577-86. doi: 10.1016/S1473-3099(13)70073-2. Epub 2013 Apr 18. PMID: 23602084.
  73. Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, Yankinda EK, Lei Q, Mmalane M, Novitsky V, Okui L, van Widenfelt E, Powis KM, Khan N, Bennett K, Bussmann H, Dryden-Peterson S, Lebelonyane R, El-Halabi S, Mills LA, Marukutira T, Wang R, Tchetgen EJ, DeGruttola V, Essex M, Lockman S; Botswana Combination Prevention Project study team. Botswana’s progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV. 2016 May;3(5):e221-30. doi: 10.1016/S2352-3018(16)00037-0. Epub 2016 Mar 24. PMID: 27126489; PMCID: PMC5146754.
  74. Ensoli B, Cafaro A, Monini P, Marcotullio S, Ensoli F. Challenges in HIV Vaccine Research for Treatment and Prevention. Front Immunol. 2014 Sep 8;5:417. doi: 10.3389/fimmu.2014.00417. PMID: 25250026; PMCID: PMC4157563.
  75. Ng’uni T, Chasara C, Ndhlovu ZM. Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions. Front Immunol. 2020 Oct 28;11:590780. doi: 10.3389/fimmu.2020.590780. PMID: 33193428; PMCID: PMC7655734.
  76. Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine. 2013 Aug 2;31(35):3502-18. doi: 10.1016/j.vaccine.2013.05.018. Epub 2013 May 21. PMID: 23707164.
  77. Phillips AN, Cambiano V, Nakagawa F, Ford D, Lundgren JD, Roset-Bahmanyar E, Roman F, Van Effelterre T. Potential future impact of a partially effective HIV vaccine in a southern African setting. PLoS One. 2014 Sep 10;9(9):e107214. doi: 10.1371/journal.pone.0107214. PMID: 25207973; PMCID: PMC4160197.


Comments


Swift, Reliable, and studious. We aim to cherish the world by publishing precise knowledge.

  • Brown University Library
  • University of Glasgow Library
  • University of Pennsylvania, Penn Library
  • University of Amsterdam Library
  • The University of British Columbia Library
  • UC Berkeley’s Library
  • MIT Libraries
  • Kings College London University
  • University of Texas Libraries
  • UNSW Sidney Library
  • The University of Hong Kong Libraries
  • UC Santa Barbara Library
  • University of Toronto Libraries
  • University of Oxford Library
  • Australian National University
  • ScienceOpen
  • UIC Library
  • KAUST University Library
  • Cardiff University Library
  • Ball State University Library
  • Duke University Library
  • Rutgers University Library
  • Air University Library
  • UNT University of North Texas
  • Washington Research Library Consortium
  • Penn State University Library
  • Georgetown Library
  • Princeton University Library
  • Science Gate
  • Internet Archive
  • WashingTon State University Library
  • Dimensions
  • Zenodo
  • OpenAire
  • Index Copernicus International
  • icmje
  •  International Scientific Indexing (ISI)
  • Sherpa Romeo
  • ResearchGate
  • Universidad De Lima
  • WorldCat
  • JCU Discovery
  • McGill
  • National University of Singepore Libraries
  • SearchIT
  • Scilit
  • SemantiScholar
  • Base Search
  • VU
  • KB
  • Publons
  • oaji
  • Harvard University
  • sjsu-library
  • UWLSearch
  • Florida Institute of Technology
  • CrossRef
  • LUBsearch
  • Universitat de Paris
  • Technical University of Denmark
  • ResearchBIB
  • Google Scholar
  • Microsoft Academic Search